Hilly Paige Shares Key Takeaways from 2025 ESC/EAS Cholesterol Guideline
Hilly Paige, Chief Innovation Officer at the Family Heart Foundation, has shared a post on LinkedIn:
“Great overview by Family Heart Foundation of the new cholesterol guidelines from European Society of Cardiology and European Atherosclerosis Society.
Figure 2 from the 2025 update is superb. Combinations of proven therapies can lower LDL-C by up to 86%! With so many safe and effective therapies available in the toolbox, it is unacceptable that currently <30% of high-risk individuals are achieving their LDL-C goals!
Also, great to see two important LDL-C lowering therapies included in the 2025 update – bempedoic acid from Esperion and evinacumab from Regeneron!
Finally, using supplements to lower your LDL-C? Don’t waste your money.”
Check here for more information.
Stay informed with Hemostasis Today.
-
Dec 19, 2025, 13:30PPTA Europe’s Holiday Message: Wishing Health, Rest, and Renewal for 2026
-
Dec 19, 2025, 13:22If You Were Reading a “Bible for Blood Donation Volunteers,” What’s the ONE Thing That Must Be in It?
-
Dec 19, 2025, 12:52Julia Owens: Stroke Remains One of the World’s Leading Causes of Death and Disability
-
Dec 19, 2025, 12:03Pradeep Natarajan: Our New Genetic Study of Aortic Stenosis in ~3M
-
Dec 19, 2025, 11:47ESO Blog: Anna Gardin on Stroke Risk in the Era of Climate Extremes
-
Dec 19, 2025, 10:51Sarah Elkourashy Presents Insights on Caplacizumab for TTP at ASH25
-
Dec 19, 2025, 10:08Camilla Lombardi Shares an EHC Nutrition Guide for People with Bleeding Disorders
-
Dec 19, 2025, 09:56Danny Hsu Shares The ”I-WISh” Study by Nichola Cooper on ITP
-
Dec 19, 2025, 09:39Paul Bolaji: A Landmark Achievement -The Historic 1st Nigerian Stroke Leaders’ Summit 2025